Cartography Biosciences
PrivateLast Round
Strategic
May 6, 2026
Total Funding Raised
$144M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Cartography Biosciences operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Strategic round in May 2026.
Cartography Biosciences is a biotechnology company that develops precision cancer immunotherapies by utilizing multi-omics profiling to construct a comprehensive tumor antigen atlas.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cartography Biosciences Comparables
Compare Cartography Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Enara Bio | 85% | |
| Noetik | 81% | |
| Arcturus Therapeutics Holdings Inc. | 80% |
For institutional investors. Book with your work email.
Cartography Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | May 6, 2026 | ||||
| Series B | Oct 2, 2025 | ||||
| Strategic | May 28, 2024 | ||||
| Series A | Jul 19, 2022 | ||||
| Seed | Nov 23, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cartography Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series A, Series B, Seed |
| Finchley Healthcare Ventures | Series B |
| RM Global Partners | Series B |
| Lotte Holdings Healthcare and Biopharmaceutical CVC | Series B |
| Gaingels | Series A, Series B |
| ARTIS Ventures | Series A, Series B |
| Catalio Capital Management | Series A, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 37% MoM.
- May 6, 2026
Samsung Venture Investment participated in the round.
For institutional investors. Book with your work email.
Cartography Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cartography Biosciences's valuation, stock price, and market status.
Is Cartography Biosciences a public or private company?
Cartography Biosciences is a private company.
What is the current stock price of Cartography Biosciences?
Cartography Biosciences is a private company, so its shares have no public market price. Caplight tracks Cartography Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cartography Biosciences worth (valuation)?
Valuation information for Cartography Biosciences is not publicly available.
Can I buy Cartography Biosciences stock?
Cartography Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cartography Biosciences's last funding round?
Cartography Biosciences's most recent funding round was Strategic on May 6, 2026.
Who are the main investors in Cartography Biosciences?
Key investors in Cartography Biosciences include Andreessen Horowitz, Pfizer Ventures, 8VC, Pfizer Ventures.
Will Cartography Biosciences IPO soon?
No public IPO plans have been announced for Cartography Biosciences.
How can I track Cartography Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Cartography Biosciences's shares on secondary markets.